1. No category

VERSATIS® MEET-THE-EXPERT-SESSION AT 8TH EFIC CONGRESS: PAIN IN EUROPE VIII, FLORENCE, ITALY, 9TH -12TH OCTOBER 2013
WHY COMPROMISE WHEN LONG-TERM TREATMENT FOR CHRONIC PHN
PAIN IS AVAILABLE?
Dr. Rodrigue Deleens, Centre Hospitalier Robert Bisson / Lisieux, France
Member of the French Society for the Study and Treatment of Pain
Chairman of CLUD (Committee against Pain), Centre Hospitalier R. Bisson, Lisieux
Member of “Douleurs sans frontiers
Targeted Topical Treatment with proven efficacy in PHN
• Proven Efficacy
• Excellent Tolerability
• Easy to use
Significant reductions in the number
of concomitant
treatment for PHN,
p<0.001
5
4
3
2
1
0
n=273
≥70 years (n=184)
Start of plaster treatment
Last follow-up
Average pain relief scores (+SD) during the 48 months
of treatment and at the final visit
Average pain relief (Mean +SD)
Versatis®
5% lidocaine
medicated plaster
Compassionate use program (CUP) in France2
Mean number of
concomitant treatmenst
Post-herpetic Neuralgia
• Chronic post-herpetic neuralgia (PHN) is a common, debilitating condition after herpes zoster with a major impact on
patients’ quality of life.
• Patients are often elderly, multimorbid and poly-medicated
• Considered pain treatments should therefore ensure sustained efficacy and excellent long-term tolerability.
6
complete
5
a lot
4
moderate
3
slight
2
none
1
0
6
12
n=
90
18 24 30 36 42 48
Final Visit
Duration of treatment (months)
81 69 56 43 38 27
76
worse
Up to 4 years‘ clinical data confirms sustained long-term effect of Versatis®1
Long-term treatment of PHN with Versatis®
• Up to 4-years clinical data confirm the long-term benefit of
topical 5% lidocaine medicated plaster (Versatis®) 1.
• Versatis® shows a sustained pain relief without development
of tolerance and it has a favourable safety and tolerability
profile, allowing long-term use in PHN patients.
• Due to its topical administration, patients experience minimal
risk of drug-drug interactions, supporting patient compliance
to prescribed therapy.
• A retrospective, observational study in France under a
compassionate use programme (CUP) assessed the value of
the 5% lidocaine medicated plaster in patients with previous
inadequate or not tolerated treatment with antidepressants
and/or antiepileptics.
Grünenthal GmbH · 52099 Aachen
Germany · www.grunenthal.com
• Treatment with the 5% lidocaine medicated plaster permitted a significant reduction in concomitant treatments
potentially being the reason for the improved tolerability
and thus enhancing quality of life 2.
CONCLUSION :
Versatis® is the only treatment in PHN patients with
data that prove efficacy and safety on a long-term
basis. It is a therapeutic alternative for PHN patients.
Dr. Rodrigue Deleens: “A long-term treatment needs to
be efficacious and safe. My patients are very satisfied
with Versatis® because of its excellent tolerability on
long-term basis.”
1 Sabatowski R et al. Safety and efficacy outcomes of long-term treatment up to 4 years with 5%
lidocaine medicated plaster in patients with post-herpetic neuralgia.Curr Med Res Opin 2012; 28:1-10.
2 Clere F et al. 5 % Lidocaine medicated plaster in elderly patients with postherpetic neuralgia. Drugs
Aging 2011;28(9): 693-702
3 Attal N et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurology
(2006)13: 1153-1169 / Eur J Neurol 2010.
4 Finnerup et al. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010
Sep;150(3):573-81.
5 Dworkin et al. Recommendations for the Pharmacological Management of Neuropathic
Pain : An Overview and Literature Update. Mayo Clin Proc. 2010 ; 85(3)(suppl) : S3-S14
WORKS WHERE IT HURTS